Population-based validation of the prognostic model ADJUVANT! for early breast cancer

Journal of Clinical Oncology

Volumn 23, Issue 12, 2005, Pages 2716-2725

  Olivotto, Ivo A ^a   Bajdik, Chris D ^a   Ravdin, Peter M ^a   Speers, Caroline H ^a   Coldman, Andrew J ^a   Norris, Brian D ^a   Davis, Greg J ^a   Chia, Stephen K ^a   Gelmon, Karen A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HORMONE; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ALGORITHM; ARTICLE; BREAST CANCER; CALCULATION; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; COMPUTER SYSTEM; CONTROLLED STUDY; DATA BASE; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; VALIDATION STUDY; AGE; BREAST TUMOR; COMPUTER PROGRAM; DISEASE FREE SURVIVAL; INTERNET; MIDDLE AGED; PATHOLOGY; THEORETICAL MODEL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERNET; MIDDLE AGED; MODELS, THEORETICAL; PROGNOSIS; SOFTWARE;

EID: 18444383684     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.178     Document Type: Article

References (25)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of randomized trials. Lancet 351:1451-1467, 1998
2. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
3. Ravdin PM, Siminoff LA, Harvey JA: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16:515-521, 1998
4. Siminoff LA, Petting JH, Abeloff MD: Doctor-patient communication about breast cancer adjuvant therapy. J Clin Oncol 7:1192-1200, 1989
5. Ravdin PM: A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 23:43-50, 1996 (suppl 2)
6. Loprinzi CL, Thorne SD: Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19:972-979, 2001
7. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001
8. Lundin J, Lundin M, Isola J, et al: A web-based system for individualized survival estimation in breast cancer. BMJ 326:29, 2003
9. Whelan T, Sawka C, Levine M, et al: Helping patients make informed choices: A randomized trial of decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 95:581-587, 2003
10. Fleming ID, Cooper JS, Henson DE, et al: (eds): AJCC Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincott-Raven, 1997
11. Ragaz J, Spinelli J, Speers C, et al: Adverse impact of lymphangitic and vascular invasion in early breast cancer: Results from the British Columbia breast cancer outcomes unit.
12. Breast Cancer Res Treat 76:542, 2002 (suppl 1; abstr 118)
13. Sawka C, Olivotto I, Goldman A, et al: The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. Br J Cancer 75:1534-1542, 1997
14. Olivotto A, Coldman AJ, Hislop TG, et al: Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 15:216-222, 1997
15. Fourquet A, Campana F, Zafrani B, et al: Prognostic factors of breast recurrence in the conservative management of early breast cancer: A 25-year followup. Int J Radiat Oncol Biol Phys 17:719-725, 1989
16. Nixon AJ, Newberg D, Hayes DF, et al: Relationship of age to pathologic factors of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12:888-894, 1994
17. Rosner D, Lane WW: Predicting recurrence in axillary node-negative breast cancer patients. Breast Cancer Res Treat 25:127-139, 1993
18. Aebi S, Gelber S, Castiglione-Gertsch M, et al: Is chemotherapy alone adequate therapy for young women with oestrogen-receptor positive breast cancer? Lancet 355:1869-1874, 2000
19. Senn HJ, Thurlimann B, Goldhirsch A, et al: Comments on the St. Gallen Consensus 2003 on the primary therapy of early breast cancer. Breast 12:569-582, 2003
20. Levine M: Clinical practice guidelines for the care and treatment of breast cancer: Adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update). CMAJ 164:213, 2001
21. Lee AK, Delellis RA, Silverman ML, et al: Prognostic significance of peritumoral lymphatic
22. and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 8:1457-1465, 1990
23. Gasparini G, Weidner N, Bevilacqua P, et al: Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454-466, 1994
24. Weir L, Speers C, D'yachkova Y, et al: Prognostic significance of the number of axillary lymph nodes reviewed in patients with node-negative breast cancer. J Clin Oncol 20:1793-1799, 2002
25. Pedersen L, Zedeler K, Holck S, et al: Medullary carcinoma of the breast: Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer 31:2289-2295, 1995